Clinical Trial Update: Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on safety and efficacy of pembrolizumab alone or with investigational agents in first-line advanced melanoma (MK-3475-02B/KEYMAKER-U02), P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Melanoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING